Amwell (AMWL) Q2 2024: Gross Margin Jumps 660bps on DHA Ramp, Paving Path to 2026 Breakeven
Amwell’s Q2 saw a sharp gross margin improvement as the Defense Health Agency (DHA) deployment scaled and cost actions took hold, fueling confidence in the company’s 2026 breakeven plan. Leadership is executing a streamlined operating model post-replatforming, with cost discipline and expanding client wins underpinning improved EBITDA guidance. With the Converge platform now the backbone of operations and enterprise deployments set for Q4, Amwell signals a structurally stronger business heading into 2025.
Summary
- Margin Expansion Signals Operating Leverage: Cost actions and higher-margin DHA ramp drove a major gross margin lift.
- Platform Migrations Now Largely Complete: Converge is now the core platform, with legacy drag contained.
- 2025 Setup Anchored by DHA Enterprise Go-Live: Full-year guidance and pipeline momentum set up a step-change in profitability next year.
Business Overview
Amwell is a digital health technology provider, generating revenue through a mix of SaaS subscription, visit-based, and professional services for payers, providers, and government clients. Its major segments include subscription software (recurring platform fees), AMG visit revenue (Amwell Medical Group, in-house clinical services), and services/care points (deployment and support work). The Converge platform, Amwell’s unified digital care delivery system, is now the linchpin of its offering, supporting hybrid (virtual and in-person) care models.
Performance Analysis
Amwell delivered a 5% YoY revenue increase in Q2, with gross margin surging 660 basis points sequentially to 37% as DHA deployments and cost discipline took hold. The company’s subscription revenue rose 11% QoQ (including a $1.5M one-time uplift), while AMG visit revenue and services/care points remained stable, reflecting a balanced business mix. Visit volumes were flat YoY at 1.5 million, with 70% of visits now on Converge, underlining the platform’s centrality.
Cost structure improvements were material: R&D spend dropped 22% sequentially (21% YoY, cap-adjusted), G&A and sales/marketing both fell sharply QoQ as the company right-sized post-replatforming. Adjusted EBITDA loss narrowed by $10 million, and Amwell exited Q2 with $277 million in cash, providing ample runway to 2026 breakeven.
- Gross Margin Inflection: Margin rebound was driven by DHA software revenue mix and operational normalization after Q1’s migration costs.
- Recurring Revenue Base Strengthening: Subscription revenue now forms a larger, more predictable share, aided by client expansions and renewals.
- Cost Discipline Evident: Headcount down mid-teens percent YoY, with SG&A and R&D both sharply lower, supporting improved EBITDA trajectory.
Underlying trends point to a business exiting transformation, with platform leverage and client stickiness setting the stage for margin expansion as new deployments go live in Q4 and early 2025.
Executive Commentary
"Our focus is strong as we deliver on key strategies that support our guidance, which calls for a step function in our growth in 2025, leading to our plan for adjusted EBITDA breakeven in 2026."
Dr. Ito Schonberg, Chairman & CEO
"We are now beginning to see the impact of our planned cost initiatives, and we are putting some non-recurring expenses behind us. As a result, adjusted EBITDA for the quarter was negative $35 million versus negative $45.6 million last quarter and negative $45.3 million last year."
Bob Shepardson, CFO
Strategic Positioning
1. DHA Contract as Margin and Growth Catalyst
The Defense Health Agency (DHA) Digital First initiative is now live at all five designated sites, with full enterprise rollout scheduled for Q4. This contract is pivotal, as it brings high-margin, recurring software revenue and a stable, government-backed client, which CFO Shepardson noted will drive gross margin above 50% in 2025 as the deployment matures.
2. Converge Platform Maturity and Client Expansion
Converge, Amwell’s flagship digital care platform, now powers 70% of all visits, with major migrations complete and remaining legacy drag contained. The platform’s deep EHR integration (notably with Epic and Cerner) and broad program support (from behavioral health to specialty care) are driving both new wins and expansions among large health systems and payers.
3. Cost Structure Reset and Organizational Realignment
Amwell has completed its replatforming era, with a transition to a single-CEO model and a leaner, more focused organization. R&D and SG&A are down sharply, and the company is targeting higher-ACV, stickier clients. Leadership is prioritizing efficiency, execution, and profitable growth over headcount-fueled expansion.
4. Ecosystem and Partner-Driven Growth
The company is building a partner ecosystem, adding programs like Hello Heart and integrating with third-party clinical solutions. This approach enables Amwell to offer a comprehensive, “digital front door” for payers and providers, increasing client stickiness and cross-sell potential.
Key Considerations
Q2 marks a structural inflection point for Amwell, as the company moves past heavy investment in platform build-out and pivots toward margin expansion and sustainable growth. The DHA contract and Converge platform are now proven, and the cost base has been reset to support operating leverage as new deployments go live.
Key Considerations:
- DHA Enterprise Go-Live Timing: Full rollout by Q4 is critical for 2025 margin and revenue step-up.
- Subscription Revenue Predictability: Recurring software revenue is stabilizing, but Q3 will see a dip before a Q4 surge as deployments hit.
- Client Expansion vs. New Logos: Most near-term growth is coming from existing client expansions, driving higher retention and ACV.
- Legacy Platform Drag: Remaining legacy customers are being managed separately, minimizing cost drag but lingering into 2025.
- Cash Runway and Capital Allocation: $277 million cash balance provides ample flexibility, reducing near-term liquidity risk as breakeven approaches.
Risks
Execution risk remains around the DHA enterprise deployment, with any delays potentially impacting the 2025 margin inflection. Subscription revenue is exposed to timing shifts, as seen in Q2’s one-time uplift and expected Q3 dip. Competition from vertical-agnostic telehealth players and continued client migration from legacy systems are ongoing challenges, though Amwell’s deep integration and ecosystem approach provide some insulation.
Forward Outlook
For Q3, Amwell guided to:
- Subscription revenue to decline slightly QoQ, before a substantial increase in Q4 as deployments hit full run rate.
- Services and care points revenue to remain lumpy, but approximately 10% of total for 2024.
For full-year 2024, management raised guidance:
- Adjusted EBITDA improved by $10 million, now expected between negative $150 million and negative $145 million.
- Total revenue expected in the $259–$269 million range.
Management cited strong pipeline growth, accelerating conversion, and full DHA rollout as drivers for a “step function” in growth and margin in 2025, with breakeven targeted for 2026.
- Full DHA enterprise deployment scheduled for Q4, setting up 2025 margin expansion.
- Cost structure expected to remain lean, with further SG&A and R&D declines in Q4 as government work winds down.
Takeaways
Amwell’s Q2 demonstrates the company has turned an operational and financial corner, with the DHA contract and Converge platform now core growth and margin levers.
- Margin and EBITDA Trajectory: Gross margin inflection and narrowed losses confirm cost actions are working and set the stage for 2025 leverage.
- Strategic Platform Position: Converge migration is largely complete, with client expansions and ecosystem integrations driving stickier, higher-value relationships.
- 2025 Watchpoint: DHA enterprise go-live and Q4 subscription ramp are pivotal for delivering the promised step-change in profitability and margin.
Conclusion
Amwell’s Q2 results validate its post-replatforming strategy, with a structurally improved cost base, expanding high-margin deployments, and clear visibility into margin expansion. The company’s disciplined execution and pipeline momentum position it for a critical inflection in 2025 as the DHA contract and Converge platform scale.
Industry Read-Through
Amwell’s margin rebound and DHA-driven growth highlight a key trend in digital health: government and enterprise clients are prioritizing deeply integrated, platform-based solutions over point products. The company’s experience shows that platform migration and cost discipline are essential for telehealth players seeking profitability, and that large-scale government contracts can meaningfully shift margin structure. For the broader sector, integration with EHRs, payer digital front doors, and ecosystem partners is increasingly table stakes, and the ability to deliver end-to-end, hybrid care models will be a competitive differentiator as health systems and payers consolidate digital vendors.